ESTABLISHMENT LABS HOLDINGS INC.

Establishment Labs Holdings Inc. is a global medical technology company focused on enhancing patient safety and aesthetic results, primarily in the breast aesthetics and reconstruction market. The company was initially incorporated in Costa Rica in 2004 and reorganized in 2013 under a parent holding company in the British Virgin Islands. Its core medical technology platform is centered on its line of silicone gel-filled breast implants, branded as Motiva Implants. Since their launch in October 2010, Motiva Implants have generated the majority of the company's revenue. Five-year results from the Motiva U.S. IDE study and post-market surveillance data show that Motiva Implants have low rates of adverse events, including rupture, capsular contracture, and implant-related reoperations, which compare favorably to competitors. Motiva Implants are registered for sale in over 100 countries, including the SmoothSilk Round and SmoothSilk Ergonomix Round Implants recently approved in the United States. The company's product portfolio is available through exclusive distributors or a direct sales force and includes five Motiva Implant product families: Round and Ergonomix Round, Ergonomix Oval, Anatomical TrueFixation, Ergonomix2 Round and Ergonomix2 Diamond, and Flora Tissue Expander. These products feature safety innovations such as SmoothSilk / SilkSurface (an optimized biocompatible smooth surface designed to reduce capsular contracture), Qid RFID technology and ZEN (a non-invasive, electronically readable serial number for product identification), BluSeal visual barrier layer (a proprietary indicator for barrier layer presence verification), and TrueMonobloc gel-shell-patch configuration (a durable system allowing for smaller incisions).